Gastroenteritis, Viral

por Orenstein, Robert
Publicado 2020

The Role of Microbiome-Based Therapeutics in Clostridioides difficile Infection: Durable, Long-Term Results of RBX2660

por Orenstein, Robert
Publicado 2022

Treating Clostridioides difficile: Could Microbiota-based Live Biotherapeutic Products Provide the Answer?

por Nagarakanti, Sandhya, Orenstein, Robert
Publicado 2023

Clostridioides difficile therapeutics: guidelines and beyond

por Orenstein, Robert, Patron, Roberto L.
Publicado 2019

Treatment of Recurrent Vulvovaginal Candidiasis With Ibrexafungerp

por Grant, Leah M., Orenstein, Robert
Publicado 2022

1657 Who Seeks a Fecal Microbiota Transplant for Recurrent C. difficile Infection?: Patient Profile of the PUNCH CD Study

por Orenstein, Robert, Dubberke, Erik, Griesbach, Cheryl, Sobcinski, Mary Kay
Publicado 2014

Two-year durability of REBYOTA™ (RBL), a live biotherapeutic for the prevention of recurrent Clostridioides difficile infections

por Orenstein, Robert, Hecht, Gail, Harvey, Adam, Tillotson, Glenn, Khanna, Sahil
Publicado 2023

468 RBX2660 (microbiota suspension) for Recurrent C. difficile Infection: 60-Day Interim Analysis of the PUNCH-CD Phase 2 Safety Study

por Dubberke, Erik, Orenstein, Robert, Mariani, Paul, Mullane, Kathleen, Sobcinski, Mary Kay
Publicado 2014

1799 Next Generation Fecal Transplant for Recurrent C. difficile Infection with and without Antiobiotic Pre-Treatment: Lessons Learned from the PUNCH CD Phase 2 Safety Study

por Mariani, Paul, Price, Connie S., Orenstein, Robert, Harris, Hill, Sobcinski, Mary Kay
Publicado 2014

Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection

por Dubberke, Erik R., Orenstein, Robert, Khanna, Sahil, Guthmueller, Beth, Lee, Christine
Publicado 2022

Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility

por Seto, Charlie T, Jeraldo, Patricio, Orenstein, Robert, Chia, Nicholas, DiBaise, John K
Publicado 2014

Erratum to: Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility

por Seto, Charlie T., Jeraldo, Patricio, Orenstein, Robert, Chia, Nicholas, DiBaise, John K.
Publicado 2016

Tetracyclines are Associated with a Reduced Risk of Clostridium difficile Infection: A Systematic Review and Meta-analysis

por Tariq, Raseen, Cho, Janice, Kapoor, Saloni, Orenstein, Robert, Singh, Siddharth, Pardi, Darrell, Khanna, Sahil
Publicado 2017

Efficacy of oral vancomycin prophylaxis for prevention of Clostridioides difficile infection: a systematic review and meta-analysis

por Tariq, Raseen, Laguio-Vila, Maryrose, Tahir, Muhammad Waqas, Orenstein, Robert, Pardi, Darrell S., Khanna, Sahil
Publicado 2021

Histoplasmosis infection in patients with rheumatoid arthritis, 1998-2009

por Olson, Timothy C, Bongartz, Tim, Crowson, Cynthia S, Roberts, Glenn D, Orenstein, Robert, Matteson, Eric L
Publicado 2011

Research Response to SARS-CoV-2/COVID-19

por Burger, Charles D., Mikhail, Amanda E., Orenstein, Robert, Ebbert, Jon O., Vergidis, Paschalis, Badley, Andrew D.
Publicado 2020

1950. Prevention of Recurrent Clostridium difficile at Six Months Following Treatment With Microbiota-Based Therapy RBX2660: Durability Results From a Phase 2 Open-Label Study

por Mische, Sarah, Orenstein, Robert, Dubberke, Erik R, Khanna, Sahil, Hecht, Gail, Dupont, Herbert, Lee, Christine, Blount, Ken
Publicado 2018

Safety of fecal microbiota, live-jslm (REBYOTA(™)) in individuals with recurrent Clostridioides difficile infection: data from five prospective clinical trials

por Lee, Christine, Louie, Thomas, Bancke, Lindy, Guthmueller, Beth, Harvey, Adam, Feuerstadt, Paul, Khanna, Sahil, Orenstein, Robert, Dubberke, Erik R.
Publicado 2023

Clinical Characteristics and Outcomes of Patients With SARS-CoV-2 Reinfection

por Comba, Isin Yagmur, Riestra Guiance, Irene, Corsini Campioli, Cristina, Challener, Douglas, Sampathkumar, Priya, Orenstein, Robert, Gordon, Joel, Bosch, Wendelyn, O’Horo, John C.
Publicado 2022

Characteristics of Patients with Mild to Moderate Primary Pulmonary Coccidioidomycosis

por Blair, Janis E., Chang, Yu-Hui H., Cheng, Meng-Ru, Vaszar, Laszlo T., Vikram, Holenarasipur R., Orenstein, Robert, Kusne, Shimon, Ho, Stanford, Seville, Maria T., Parish, James M.
Publicado 2014